TNF-Related Biomarkers For Assessing Cancer Cell Response To Treatment With Taxane And/Or Anthracycline Drugs
OwnerAmadeo Mark Parissenti, Jason A. Sprowlinventors
Life of this patent
Estimating the term…
Abstract
A method of evaluating response to a taxane drug and/or anthracycline drug, the method comprising measuring a level of a TNF biomarker in a biological sample comprising the cancer cell after contacting the cancer cell with the taxane drug and/or anthracycline drug.
Claims26
A method of evaluating cancer cell drug response (e.g. toxicity/resistance) to a taxane drug and/or anthracycline drug, the method comprising:
- a. measuring a level of a TNF biomarker in a biological sample comprising the cancer cell after contacting the cancer cell with the taxane drug and/or anthracycline drug;
- b. detecting a difference or a lack of difference in the level of the TNF biomarker compared to a control;
- and
- c. or identifying the cancer cell as sensitive or resistant to the to taxane drug and/or anthracycline drug according to the detected difference in the TNF biomarker level.
A method of evaluating cancer cell response to administration of a taxane drug and/or anthracycline drug in a subject in need thereof, the method comprising:
- a. measuring a level of a TNF biomarker in a biological sample comprising pathologic tissue obtained from the subject after administering to the subject of one or more doses of the taxane drug and/or anthracycline drug;
- b. detecting a difference or a lack of difference in the relative level of the TNF biomarker compared to a control;
- and
- c. identifying the cancer cell as sensitive or resistant to the resistance to taxane drug and/or anthracycline drug according to the detected difference in in the TNF biomarker level.
A method for predicting response in a patient by analyzing a subject sample for the presence or absence of a taxane and/or anthracycline drug sensitive cancer cell by measuring the level of one or more TNF biomarkers, wherein the subject is predicting to be responding to the taxane and/or anthracycline drug if an increased level of a TNF sensitive biomarker and/or a decreased level of a TNF resistance biomarker is detected.
Dependencies are inferred from the claim text.